Comment on: Have we reached the limits for the treatment of diabetic nephropathy?

Expert Opinion on Investigational Drugs

Volumn 23, Issue 6, 2014, Pages 883-884

  Onuigbo, Macaulay A C ^a,b  

^a Mayo Clinic   (United States)

^b Mayo Clinic Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LETTER; NEPHROTOXICITY; PATIENT MONITORING; PHYSICIAN; PREDICTION; RENAL PROTECTION; ANIMAL; DIABETIC NEPHROPATHIES;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS;

EID: 84900817257     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.912376     Document Type: Letter

References (5)

1. Hajhosseiny R, Khavandi K, Jivraj N, et al. Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs 2014;23(4):511-22
2. Onuigbo MAC. Renoprotection and the bardoxolone methyl story-is this the right way forward? A novel view of renoprotection in CKD trials: a new classification scheme for renoprotective agents. Nephron Extra 2013;3:36-49
3. Onuigbo MA. Reno-prevention versus renoprotection: a critical re-Appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET-A call for more circumspection. QJM 2009;102:155-67
4. Onuigbo MA, Onuigbo N. Chronic kidney disease and RAAS blockade: a new view of renoprotection. Lambert Academic Publishing GmbH & Co. KG, London; 2011
5. Onuigbo MA. Epilogue-bold predictions and the future of renoprotection: the way forward with multiple pathway blockers-making a case for novel non-Angiotensin inhibiting renoprotective agents like corticotropin and pentoxifylline. In: Onuigbo MAC, editor. ACE inhibitors: medical uses, mechanisms of action, potential adverse effects and related topics. Volume 2. NOVA Publishers; New York, NY; 2013